natgillin/translations-raw huggingface dataset:
De bør ikke anvende Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne • hvis De er allergisk (overfølsom) over for doxazosin eller et af de øvrige indholdsstoffer i Doxazosin Retard Arrow- 4 depottabletter og tilknyttede navne. • hvis De ved, at De er overfølsom over for quinazoliner (f. eks. prazosin, terazosin), som er den familie af medicinske kemikalier, som doxazosin tilhører • hvis De har ophobning eller blokering i urinvejene, en infektion i urinvejene eller blæresten • hvis De har en alvorlig nyrelidelse (anuri eller progressiv nyreinsufficiens)
Do not take Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names • if you are allergic (hypersensitive) to doxazosin or any of the other ingredients of Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names • if you know that you are sensitive to quinazolines (e. g. prazosin, terazosin) which is the chemical family of medicines to which doxazosin belongs • if you have any kind of congestion or blockage in your urinary tract, an infection of the urinary tract or have bladder stones • if you have a serious kidney disorder (anuria or progressive renal insufficiency) • if you suffer from a loss of bladder control (bladder overflow) • if you have or have ever had any form of obstruction of the digestive tract if you are breast-feeding.
20/ 24 • hvis De lider af manglende blærekontrol (overaktiv blære) • hvis De nogen sinde har haft tilstopning af fordøjelsskanalen • hvis De ammer • hvis De har ophobning eller blokering i urinvejene, en infektion i urinvejene eller blæresten • hvis De lider af nyreproblemer, overaktiv blære (De føler ingen trang til at lade vandet) eller anuri (Deres krop producerer ikke noget urin) • hvis De har eller tidligere har haft tilstopning af fordøjelsskanalen.
20/ 24 • If you have any kind of congestion or blockage in your urinary tract, an infection of the urinary tract or have bladder stones • if you suffer from kidney problems, overflow incontinence (you do not feel the urge to urinate) or anuria (your body is not producing any urine) • if you have or have had in the past any form of obstruction of the digestive tract.
Vær særlig forsigtig med at anvende Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne • hvis De har hjerteproblemer eller tidligere har haft en hjertesygdom • hvis De har en leversygdom eller tager medicin for at kontrollere leverfunktionen, så som cimetidin, eller hvis De går i dialyse • hvis De lider af diabetisk autonom neuropati, en sygdom, der er forbundet med diabetes, og som påvirker Deres nervesystem. • hvis De er under 18 år.
Take special care with Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names • if you have problems with your heart or a history of heart disease • if you have liver disease or you are taking medicines to control the way your liver works such as cimetidine or if you are undergoing dialysis • if you suffer from diabetic autonomic neuropathy, a disease associated with diabetes which affects your nervous system. • If you are under 18 years of age.
Hvis De har planlagt et kirurgisk indgreb og narkose (selv hos tandlægen), skal De fortælle lægen eller tandlægen, at De tager Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne.
If you are planning to have surgery and anaesthesia (even at the dentist) you should tell your doctor or dentist that you are taking Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names.
Indtagelse af anden medicin Fortæl det til Deres læge, hvis De allerede bruger nogle af de følgende lægemidler, da disse lægemidler kan påvirke Deres medicin:
Taking other medicines Tell your doctor if you are already taking any of the following as they may interact with your medicine:
• medicin til sænkning af blodtrykket, herunder fosinopril og lisinopril, idet Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne kan øge deres virkning • visse ikke- steroide lægemidler, der benyttes til behandling af reumatisme, eller det kvindelige hormon østrogen, da disse kan reducere virkningen af Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne • lægemidler, der indvirker på nervesystemet, så som dopamin, efedrin, epinefrin, metaraminol, metoxamin og fenylefedrin, da disse også kan reducere virkningen af Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne
• medicines to lower your blood pressure including fosinopril and lisinopril as Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names can increase their effect • certain non-steroidal medicines used to treat rheumatism or the female hormone, estrogen, as these can reduce the effect of Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names • medicines which work on the nervous system such as dopamine, ephedrine, epinephrine, metaraminol, methoxamine and phenylephrine as these can also reduce the effect of Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names.
Dette gælder også, hvis der er tale om ikke- receptpligtige lægemidler.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Hvordan man tager Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne samen med mad og drikkevarer Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne kan tages med eller uden mad.
Taking Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names with food and drink Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names can be taken with or without food.
Tabletterne skal sluges hele med tilstrækkeligt væske.
The tablets must be swallowed whole with a sufficient amount of liquid.
Graviditet og amning Graviditet De bør ikke anvende Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne, hvis De er gravid, medmindre lægen giver Dem besked om det.
Pregnancy and breast-feeding Pregnancy Do not take Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names if you are pregnant unless your doctor tells you to.
Amning De bør ikke amme, mens De tager Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne
Breast-feeding You must not breast-feed whilst you are taking Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names.
21/ 24 Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne kan påvirke Deres bedømmelsesevne og koncentrationsevne.
Driving and using machines Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names can affect your judgement and concentration.
Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne bør altid tages i nøje overensstemmelse med Deres læges instruktioner.
21/ 24 Always take Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names exactly as your doctor told you.
Tabletterne skal sluges hele med tilstrækkeligt væske.
Your tablets should be swallowed whole with a sufficient amount of liquid.
Hvis De glemmer at tage Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne De må ikke tage den glemte dosis eller en dobbeltdosis som erstatning for en glemt dosis.
If you forget to take Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names:
Tag den næste dosis til sædvanlig tid.
Do not take the missed dose or a double dose to make up for the one you missed.
Hvis De holder op med at tage Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne Bliv ved med at tage tabletterne, indtil Deres læge beder Dem stoppe.
Keep taking your tablets until your doctor tells you to stop.
Som alle andre lægemidler kan Doxazosin Retard Arrow- 4 depottabletter og tilknyttede navne have bivirkninger, selvom ikke alle får bivirkninger.
Like all medicines, Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names can cause side effects, although not everybody gets them.
Der er set følgende bivirkninger:
The following side effects have been reported:
Usædvanlig (rammer under en person ud af 100, men flere end en person ud af 1. 000): lave kaliumniveauer i blodet, gigt, øget tørst, mareridt, glemsomhed (amnesi), følelsesmæssig ustabilitet, rysten, muskelstivhed,
Uncommon (affecting less than one person in 100 but more than one person in 1,000): low levels of potassium in the blood, gout, increased thirst, nightmares, forgetfulness (amnesia), emotional instability, tremor, muscle stiffness, increased tear production, abnormal intolerance to light, ringing in the ears (tinnitus), heart flutters, angina, an increase or slowing of the heart rate, heart attack, low blood pressure especially on getting up from a sitting or lying position, vascular problems, nose bleeds, tightening of the chest, cough, throat inflammation, eating disorders (anorexia), increased appetite, taste disturbances, hair loss, swelling of the face and joints, joint pain, muscle weakness, incontinence, difficulty with or pain on urinating, flushing, fever (shivers) and loss of colour.
Sjælden (rammer under en person ud af 1. 000, men flere end en person ud af 10. 000): depression, høje blodsukkerniveauer, uro, sovende arme og ben, uklart syn, apopleksi, hævelse af strubehovedet, mavesmerter, diaré, opkastning, gulsot, øgede leverenzymer i blodet, udslæt, kløe eller rødme af huden, impotens, smertefuld, vedvarende peniserektion og lav kropstemperatur (specielt hos ældre).
Rare (affecting less than one person in 1,000 but more than one person in 10,000): depression, high blood sugar levels, agitation, pins and needles, blurred vision, stroke, swelling of the voice box, stomach pain, diarrhoea, vomiting (being sick), jaundice, increased liver enzymes in the blood, rash, itching or reddening of 22/ 24 the skin, impotence, painful, persistent erection of the penis and low body temperature (especially in the elderly).
Meget sjælden (rammer under en person ud af 10. 000): reduktion i antallet af røde og hvide blodlegemer i blodet og øget mængde urinstof og kreatinin i blodet.
Very rare (affecting less than one person in 10,000): a reduction in red and white cells in the blood and an increase in urea and creatinine levels in the blood.
5 HVORDAN DE OPBEVARER DOXAZOSIN RETARD ARROW 4 MG DEPOTTABLETTER OG TILKNYTTEDE NAVNE
5 HOW TO STORE DOXAZOSIN RETARD ARROW 4 MG PROLONGED RELEASE TABLETS AND ASSOCIATED NAMES:
Hvad Doxazosin Retard Arrow 4 mg depottabletter og tilknyttede navne indeholder Det aktive stof er doxazosin (som doxazosinmesilat).
What Doxazosin Retard Arrow 4 mg prolonged release tablets and associated names contains:
De øvrige indholdsstoffer i tabletkernen er makrogol, mikrokrystallinsk cellulose, povidon, butylhydroxytoluen (E- 321), α- tokoferol, vandfrit kolloid silica og natriumstearylfumarat.
The other ingredients in the tablet core are macrogol, microcrystalline cellulose, povidone, butylhydroxytoluene (E-321), α -tocopherol, silica colloidal anhydrous and sodium stearyl fumarate.
De øvrige indholdsstoffer i tabletovertrækket er metakrylcopolymer, vandfrit kolloid silica, makrogol og titaniumdioxid (E- 171)).
The other ingredients in the tablet coat are methacrylic copolymer, silica colloidal anhydrous, macrogol and titanium dioxide (E-171)).
Tabletterne er hvide, runde og bikonvekse med indstemplet ‘ DL ’.
The tablets are white, round and biconvex with the embossing ‘ DL’.
23/ 24 Indehaveren af Markedsføringsindehaver og fremstiller Indehaveren af Markedsføringsindehaver Arrow Generics Limited, Unit 2, Eastman Way, Stevenage, Hertfordshire, SG1 4SZ, Storbritanninen
Arrow Generics Limited, Unit 2, Eastman Way, Stevenage, Hertfordshire, SG1 4SZ, United Kingdom
Fremstiller Arrow Generics Limited, Unit 4/ 5 Willsborough Cluster, Clonshaugh Industrial Estate, Clonshaugh, Dublin 17, Irland.
23/ 24 Arrow Generics Limited, Unit 4/ 5 Willsborough Cluster, Clonshaugh Industrial Estate, Clonshaugh, Dublin 17, Republic of Ireland.
Dette lægemiddel er godkendt i EEA medlemslandene under følgende navne [Udfyldes nationalt]
[To be completed nationally]
London, 11/ 10/ 2006 EMEA/ CHMP/ 423796/ 2006
London, 11/ 10/ 2006 EMEA/ CHMP/ 423796/ 2006
21, OM Doxazosin Retard “ Arrow ” 4 mg depottabletter og tilknyttede navne Internationalt fællesnavn (INN):
OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Doxazosin Retard “ Arrow” 4 mg prolonged release tablets and associated names International Non-Proprietary Name (INN):
Doxazosin Retard “ Arrow ” 4 mg depottabletter og tilknyttede navne (doxazosin) er et alfa- 1- receptor - blokerende middel, som anvendes til behandling af patienter med essentiel hypertension og til symptomatisk behandling af benign prostatahyperplasi.
Doxazosin Retard “ Arrow” 4 mg prolonged release tablets and associated names (Doxazosin) is is receptor alfa blocking agent used in the treatment of patients with essential hypertension and in the symptomatic treatment of patients with benign prostatic hyperplasia.
Arrow Generics UK Ltd indgav ansøgninger om gensidig anerkendelse af Doxazosin Retard “ Arrow ” 4 mg depottabletter og tilknyttede navne på grundlag af den markedsføringstilladelse, Danmark udstedte den 30. september 2002.
Arrow Generics UK Ltd submitted applications for mutual recognition of Doxazosin Retard “ Arrow” 4 mg prolonged release tablets and associated names on the basis of the marketing authorisation granted by the Denmark on 30 September 2002.
Formålet med indbringelsen var at opnå enighed om, hvor vidt frigivelsesprofilen for Doxazosin Retard “ Arrow ” 4 mg depottabletter afviger væsentligt fra det oprindelige lægemiddel og eventuelt medfører øget forekomst af bivirkninger såsom svimmelhed og hypotension, hvorvidt der er væsentlige forskelle i resultaterne af testbatcher i enkeltdosisfasen af undersøgelserne 5208 og 1995 og hvor vidt ansøgeren ved udformningen af bioækvivalensundersøgelserne afviger fra CHMP’ s retningslinjer, navnlig når det gælder virkningen af fødevarer.
The scope of the referral was to agree whether Doxazosin Retard “ Arrow” 4mg prolonged release tablets differ significantly with regards to the release profile from the originator product with potential for increased incidence of adverse events such as dizziness and hypotension, whether there were significant differences in performance of test batches in the single dose phase of studies 5208 and 1995 and whether the applicant has deviated from CHMP guidelines on the design of the bioequivalence studies, particularly in relation to the effect of food.
I lyset af de samlede data, der var blevet fremlagt, og den faglige debat i udvalget var CHMP på sit møde i juni 2006 af den opfattelse, at benefit- risk forholdet er gunstigt for Doxazosin Retard “ Arrow ” 4 mg depottabletter og tilknyttede navne, at de rejste indvendinger ikke bør forhindre udstedelse af en markedsføringstilladelse, og at referencemedlemsstatens produktresumé, etikettering og indlægsseddel bør ændres.
During the June 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/ risk ratio is favourable for Doxazosin Retard “ Arrow” 4 mg prolonged release tablets and associated names, that the objections raised by should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
Winthrop Pharmaceuticals UK Ltd 1 Onslow Street, Guildford, Surrey GU1 4YS Det Forenede Kongerige Tlf.:
Winthrop Pharmaceuticals UK Ltd 1 Onslow Street, Guildford, Surrey GU1 4YS United Kingdom Tel:
Winthrop Arzneimittel GmbH Industriestrasse 10 82256 Furstenfeldbruck Tyskland Tlf.:
Winthrop Arzneimittel GmbH Industriestrasse 10 82256 Furstenfeldbruck Germany Tel:
Chinoin Pharmaceuticals and Chemical Works Co Ltd 1045 Budapest, To utca 1- 5 UNGARN Tlf.:
Chinoin Pharmaceuticals and Chemical Works Co Ltd 1045 Budapest, To utca 1-5 HUNGARY Tel:
Doxazosin Winthrop 4mg Tablets
Doxazosin Winthrop 4mg Tablets
Winthrop Medicaments 1 - DOXAWIN XL 13, Bd Romain Rolland, 75014, Paris, Frankrig Tlf.:
Winthrop Medicaments 1- DOXAWIN XL 13, Bd Romain Rolland, 75014, Paris France Tel:
2/ 24 Indehaver af Medlemsstat
Marketing Authorisation
Winthrop Medicaments 1 - Doxazosin 13, Bd Romain Rolland, Winthrop XL 4 mg 75014, Paris, Frankrig Tlf.:
Winthrop Medicaments 1- Doxazosin 13, Bd Romain Rolland, Winthrop XL 4 mg 75014, Paris France Tel:
Winthrop Pharmaceuticals Doxazosina 4 UK Ltd 1 Onslow Street, WINTHROP 4 mg Guildford, Surrey GU1 4YS comprimidos de Det Forenede Kongerige liberación Tlf.:
Winthrop Pharmaceuticals Doxazosina 4 UK Ltd 1 Onslow Street, WINTHROP 4 mg Guildford, Surrey GU1 4YS comprimidos de United Kingdom liberación Tel:
Prolonged release tablets
Prolonged release tablets
Winthrop Pharmaceuticals Slocinx XL 4mg UK Ltd 1 Onslow Street, Tablets Guildford, Surrey GU1 4YS Det Forenede Kongerige
Winthrop Pharmaceuticals Slocinx XL 4mg UK Ltd 1 Onslow Street, Tablets Guildford, Surrey GU1 4YS United Kingdom
SAMLET RESUMÉ AF DEN FAGLIGE VURDERING AF Doxazosin “ Winthrop ” 4 mg depottabletter og de tilknyttede navne (se bilag I)
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF Doxazosin “ Winthrop” 4 mg prolonged release tablets and associated names (see Annex I)
- hensigten med indbringelsen var at opnå enighed om, hvor vidt frigivelsesprofilen for Doxazosin
- The scope of the referral was to agree whether Doxazosin “ Winthrop” 4mg prolonged release tablets
Produktresumé, etikettering og indlægsseddel fremgår af bilag III.
the CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Doxazosin “ Winthrop” 4 mg prolonged release tablets and associated names (see Annex I).
Doxazosin Winthrop 4 mg depottabletter og dermed forbundne navne [Se Bilag I]
7/ 24 1 NAME OF THE MEDICINAL PRODUCT Doxazosin Winthrop 4 mg prolonged release tablets and associated names [See Annex I]
Hver depottablet indeholder 4 mg doxazosin (som mesilat).
2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 4 mg doxazosin (as mesilate).
Symptomatisk behandling gaf benign prostatahyperplasi.
4.1 Therapeutic indications Essential hypertension Symptomatic treatment of benign prostatic hyperplasia.
Doxazosin Winthrop 4 mg depottabletter og dermed forbundne navne kan både tages med og uden mad. Tabletterne skal sluges hele med tilstrækkelig væske.
4.2 Posology and method of administration Doxazosin Winthrop 4 mg prolonged release tablets and associated names [See Annex I]can be taken with or without food.
Det kan også kombineres med et andet lægemiddel som eksempelvis en thiazid- diuretikum, beta - adrenoceptor blokeringsagent, kalciumantagonist eller en ACE- inhibitor.
Doxazosin Winthrop 4 mg prolonged release tablets and associated names [See Annex I]can be used as sole agent or in combination with another medicinal product e. g. a thiazide diuretic, beta-adrenoceptor blocking agent, calcium antagonist or an ACE-inhibitor.
Symptomatisk behandling af benign prostatisk hyperplasi.
Symptomatic treatment of prostatic hyperplasia:
Patienter med nyreskader.:
Patients with renal impairment:
Den normale dosering kan derfor anvendes hos sådanne patienter.
Since there is no change in pharmacokinetics in patients with impaired renal function, and since there are no signs that doxazosin prolonged release tablets aggravates existing renal impairment, the usual dose can be used in these patients.
Doxazosin Winthrop 4 mg depottabletter og dermed forbundne navne skal gives med særlig forsigtighed til patienter med alvorlige leverskader.
In
Derfor anbefales brugen af doxazosin- tabletter med forlænget afgivelse ikke (se afsnit 4. 4).
8/ 24 patients with severe hepatic impairment clinical experience is lacking and therefore the use of doxazosin prolonged release tablets is not recommended (see section 4.4).
• Overfølsomhed for det aktive stof, quinazolin (fx prazosin, terazosin), eller for et af hjælpestofferne • Benign hyperplasi og samtidig kongestion af de øvre urinveje, kronisk urinvejsinfektion eller blæresten • Overløben blære, anuri eller progressiv nyreinsufficiens • Tidligere øsofageal eller gastrointestinel obstruktion eller reduceret lumendiameter af mave- tarm - kanalen • Amning.
• Hypersensitivity to the active substance, other quinazolines (e. g. prazosin, terazosin), or to any of the excipients • Benign hyperplasia and concomitant congestion of the upper urinary tract, chronic urinary tract infections or bladder stones • Overflow bladder, anuria or progressive renal insufficiency • History of oesophageal or gastrointestinal obstruction or decreased lumen diameter of the gastrointestinal tract • Lactation.
Doxazosin Winthrop 4 mg depottabletter og dermed forbundne navne skal gives med forsigtighed til patienter med følgende akutte hjertesygdomme:
Doxazosin Winthrop 4 mg prolonged release tablets and associated names [See Annex I]should be administered with caution in patients with the following acute heart diseases:
På grund af en eventuel forhøjet risiko for udvikling af hjertefejl bør doxazasin- tabletter med forlænget afgivelse ikke anvendes som eneste behandlende middel ved førstevalgsbehandling af hypertension hos hypertensive patienter med en eller flere yderligere risikofaktorer for kardiovaskulær sygdom.
In hypertensive patients with one or more additional risk factors for cardiovascular disease, doxazosin prolonged release tablets should not be used as a single agent for the first-line treatment of hypertension due to a possible increased risk for development of heart failure.
For at minimere en eventuel postural effekt, som fx hypotension og besvimelse skal patienten overvåges ved igangsætning af terapi eller ved forhøjelse af dosering.
On initiation of therapy or increasing of dose the patient should be monitored to minimise the potential for postural effects, e. g. hypotension and syncope.
10 – 20% af patienterne oplever hypotension og træthed, og mindre end 5% af patienterne oplever ødem og dyspnø.
In patients treated for benign prostatic hyperplasia and without hypertension mean blood pressure changes are small, but hypotension, dizziness, fatigue occur in 10 – 20% of the patients and oedema and dyspnoea occur in less than 5% of patients.
Hypotensive patienter eller patienter med kendt ortostatisk dysregulation, som tager doxazosin- tabletter med forlænget afgivelse, kræver særlig opmærksomhed med henblik på behandling af benign prostatahyperplasi (BPH).
Special care should be taken with hypotensive patients or patients with known orthostatic dysregulation taking doxazosin prolonged release tablets to treat benign prostatic hyperplasia (BPH).
Doxazosin Winthrop 4 mg depottabletter og dermed forbundne navne skal gives med forsigtighed til patienter med tegn på mild eller moderat leverskade (se afsnit 5. 2).
Doxazosin Winthrop 4 mg prolonged release tablets and associated names [See Annex I]should be administered with caution in patients with signs of mild to moderate hepatic impairment (see section 5.2).
Derfor anbefales brug til sådanne patienter ikke.
Since no clinical experience from patients with severe hepatic insufficiency exists, use in these patients is not recommended.
Det anbefales at være forsigtig med at give doxazosin- tabletter med forlænget afgivelse samtidigt med lægemidler, som kan påvirke levermetabolismen (fx cimetidin).
Caution is also recommended when doxazosin prolonged release tablets is administered concomitantly with medicinal products which may influence hepatic metabolism (e. g. cimetidine).
9/ 24 Doxazosin Winthrop 4 mg depottabletter og dermed forbundne navne kan påvirke plasmareninaktiviteten og urinekskretion af vanillinmandelsyre.
Doxazosin Winthrop 4 mg prolonged release tablets and associated names [See Annex I]may influence plasma renin activity and urinary excretion of vanillylmandelic acid.
In vitro- data i humant plasma viser, at doxazosin ingen effekt har på proteinbindingen af digoxin, warfarin, phenytoin eller indomethacin.
Doxazosin has been administered